Alniche Life Sciences has launched VIROBIND mouth spray and VIROBIND AB capsules to handle microbial infections.VIROBIND mouth spray forms a barrier in the oral cavity against the accumulation of pathogens. The barrier solution consists of trypsin and glycerol. The mouth spray is a scientifically tested enzyme-based formulation. The spray can be used in the early stages of infection to recover and relieve sore throat, cough, rhinorrhoea, and other common cold symptoms. 

VIROBIND AB (Veg Capsule) is a probiotic formulation for the treatment of respiratory infections. The capsules consist of Lactobacillus Plantarum two billion CFU that improves immune response (anti-viral effect/ stimulation of Immunoglobulin production) and enhances the intestinal barrier function. All the probiotics in VIROBIND AB capsule are patented strains of AB-Biotica, Spain. Consumption of one capsule daily will help in the formation of beneficial bacteria (i.e., probiotics) that helps to bolster or recover effective immune function in the GI tract and also indirectly in the lung. 

Girish Arora, Founder and MD, Alniche Lifesciences shares “ We provide complete therapy for COVID-19 patients with a product range that consists of supportive and immunity booster medicines. VIROBIND range is an addition to our portfolio.”

VIROBIND Mouth Spray is conceptualised, formulated, and manufactured in state-of-the-art manufacturing plant Effikasia Lifesciences (a group company of Alniche). There are various novel products in the pipeline, that would be launched soon in various therapy areas. Effikasia is in active discussion with global companies for manufacturing global brands in India for India and emerging markets.